Table of Content

Archive

Winter 2019, Vol. 27 No. 4

Hong Kong J. Dermatol. Venereol. (2019) 27, 181-184


Case Report

Vasculitic ulcer after programmed death-ligand 1 inhibitor therapy in a patient with metastatic ovarian cancer

轉移性卵巢癌患者接受程序性死亡配體-1抑製劑治療後的血管炎性潰瘍

E Choi, J Huang, C Tan

Abstract

Programmed death-ligand 1 (PD-L1) inhibitors are monoclonal antibodies used in the treatment of certain cancers by enhancing a patient's immune system. They are therefore associated with immune-related side effects including cerebral vasculitis. We report a patient who developed a cutaneous vasculitic ulcer likely secondary to PD-L1 inhibitor therapy for metastatic ovarian cancer. She was treated and improved with prednisolone, colchicine and discontinuation of the drug. This case highlights a cutaneous manifesation of PD-L1 therapy, which although not life-threatening, may allow for early detection of PD-L1 treatment toxicity.

細胞程式死亡-配體1(PD-L1)抑製劑是通過增強患者的免疫系統來治療某些癌症的單克隆抗體。因此,它們可引起包括腦血管炎在內的相關免疫副作用。我們報告了一名患者的皮膚血管炎性潰瘍,可能是由醫治轉移性卵巢癌細胞的程式死亡-配體1抑製劑治療所引起。停止該藥並配以潑尼松龍和秋水仙鹼治療後,她的情況得到改善。此病例展現了細胞程式死亡-配體1療法的皮膚表現,儘管不危及生命,但可由此及早留意到細胞程式死亡-配體1療法的毒性。

Keywords: Monoclonal antibody, ovarian cancer, programmed death-ligand 1, ulcer, vasculitis

關鍵詞: 單克隆抗體、卵巢癌、細胞程式死亡-配體1、潰瘍、血管炎